https://www.selleckchem.com/products/azd0364.html © 2020 John Wiley & Sons Ltd.Novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome virus (SARS-CoV-2) has become a global healthcare crisis. The Centers for Disease Control and Prevention (CDC) lists immunocompromised patients, including those requiring immunosuppression following renal transplantation, as high-risk for severe disease from SARS-CoV-2. Treatment for other viral infections in renal transplant recipients often includes a reduction in immunosuppression, however, there are no current guidelines recommending the optimal approach to managing immunosuppression in the patients who are infected with SARS-CoV-2. It is currently recommended to avoid corticosteroids in the treatment of SARS-CoV-2 outside of critically ill patients. Recently published cases describing the inpatient care of COVID-19 in renal transplant recipients differ widely in disease severity, time from transplantation, baseline immunosuppressive therapy, and the modifications made to immunosuppression during COVID-19 treatment. The purpose of this review is to summarize and compare inpatient immunosuppressant management strategies of recently published reports in the renal transplant population infected with SARS-CoV-2 and to discuss the limitations of corticosteroids in managing immunosuppression in this patient population. This article is protected by copyright. All rights reserved.Correction of calculation errors in the original article led to the change of bead type for the unprotonated beads in the coarse-grained polyethylenimine model. The original model was still of good quality while the updated model showed better performance in describing the interaction between polyethylenimine and DNA. © 2020 Wiley Periodicals, Inc.The European Academy of Allergy and Clinical Immunology (EAACI) is the leading organisation in the field of Allergy, Asthma and Clinical Immunology with nearly 12,000 members from 124 coun